303 related articles for article (PubMed ID: 21820052)
1. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
[TBL] [Abstract][Full Text] [Related]
2. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
3. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
[TBL] [Abstract][Full Text] [Related]
4. Influence of cyclodextrin complexation on piroxicam gel formulations.
Jug M; Bećirević-Laćan M; Kwokal A; Cetina-Cizmek B
Acta Pharm; 2005 Sep; 55(3):223-36. PubMed ID: 16375834
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
6. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: formulation, manufacturing and characterization.
Albertini B; Passerini N; Di Sabatino M; Monti D; Burgalassi S; Chetoni P; Rodriguez L
Int J Pharm; 2010 Oct; 399(1-2):71-9. PubMed ID: 20696227
[TBL] [Abstract][Full Text] [Related]
7. Effect of glucosamine HCl on dissolution and solid state behaviours of piroxicam upon milling.
Al-Hamidi H; Edwards AA; Douroumis D; Asare-Addo K; Nayebi AM; Reyhani-Rad S; Mahmoudi J; Nokhodchi A
Colloids Surf B Biointerfaces; 2013 Mar; 103():189-99. PubMed ID: 23201737
[TBL] [Abstract][Full Text] [Related]
8. Preparation and physicochemical characterizations of tanshinone IIA solid dispersion.
Zhao X; Liu X; Gan L; Zhou C; Mo J
Arch Pharm Res; 2011 Jun; 34(6):949-59. PubMed ID: 21725816
[TBL] [Abstract][Full Text] [Related]
9. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
[TBL] [Abstract][Full Text] [Related]
10. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms.
Paaver U; Lust A; Mirza S; Rantanen J; Veski P; Heinämäki J; Kogermann K
Int J Pharm; 2012 Jul; 431(1-2):111-9. PubMed ID: 22554403
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel.
Passerini N; Albertini B; Perissutti B; Rodriguez L
Int J Pharm; 2006 Aug; 318(1-2):92-102. PubMed ID: 16697539
[TBL] [Abstract][Full Text] [Related]
12. Piroxicam cocrystals with phenolic coformers: preparation, characterization, and dissolution properties.
Emami S; Adibkia K; Barzegar-Jalali M; Siahi-Shadbad M
Pharm Dev Technol; 2019 Feb; 24(2):199-210. PubMed ID: 29557714
[TBL] [Abstract][Full Text] [Related]
13. Towards improved solubility of poorly water-soluble drugs: cryogenic co-grinding of piroxicam with carrier polymers.
Penkina A; Semjonov K; Hakola M; Vuorinen S; Repo T; Yliruusi J; Aruväli J; Kogermann K; Veski P; Heinämäki J
Drug Dev Ind Pharm; 2016; 42(3):378-88. PubMed ID: 26065533
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling.
Naelapää K; Boetker JP; Veski P; Rantanen J; Rades T; Kogermann K
Int J Pharm; 2012 Jun; 429(1-2):69-77. PubMed ID: 22433471
[TBL] [Abstract][Full Text] [Related]
15. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
Zahedi P; Lee PI
Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
[TBL] [Abstract][Full Text] [Related]
16. The dissolution enhancement of piroxicam in its physical mixtures and solid dispersion formulations using gluconolactone and glucosamine hydrochloride as potential carriers.
Al-Hamidi H; Obeidat WM; Nokhodchi A
Pharm Dev Technol; 2015 Jan; 20(1):74-83. PubMed ID: 24392858
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of dissolution rate of piroxicam using liquisolid compacts.
Javadzadeh Y; Siahi-Shadbad MR; Barzegar-Jalali M; Nokhodchi A
Farmaco; 2005 Apr; 60(4):361-5. PubMed ID: 15848213
[TBL] [Abstract][Full Text] [Related]
18. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine.
Lee KR; Kim EJ; Seo SW; Choi HK
Arch Pharm Res; 2008 Aug; 31(8):1023-8. PubMed ID: 18787792
[TBL] [Abstract][Full Text] [Related]
19. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes.
Kogermann K; Veski P; Rantanen J; Naelapää K
Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718
[TBL] [Abstract][Full Text] [Related]
20. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
